<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10408844</article-id><article-id pub-id-type="pmc">2362337</article-id><article-id pub-id-type="pii">6690369</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690369</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Thatcher</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Campos</surname><given-names>E S De</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bell</surname><given-names>D R</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Steward</surname><given-names>W P</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Varghese</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Morant</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Vansteenkiste</surname><given-names>J F</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Rosso</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Ewers</surname><given-names>S-B</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Sundal</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Schatzmann</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Stocker</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><aff id="aff1">CRC Department of Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK</aff><aff id="aff2">Royal North Hospital, Sydney, Australia</aff><aff id="aff3">Leicester Royal Infirmary, Leicester, UK</aff><aff id="aff4">Belfast City Hospital, Belfast, UK</aff><aff id="aff5">Kantonsspital, St Gallen, Switzerland</aff><aff id="aff6">University Hospital Gasthuisberg, Leuven, Belgium</aff><aff id="aff7">Medical Oncology Institute, Genova, Italy</aff><aff id="aff8">University Hospital, Lund, Sweden</aff><aff id="aff9">Janssen-Cilag, Oslo, Norway</aff><aff id="aff10">RW Johnson Pharmaceutical Research Institute, Bassersdorf, Switzerland</aff></contrib-group><pub-date pub-type="ppub"><month>5</month><year>1999</year></pub-date><pub-date pub-type="epub"><day>01</day><month>05</month><year>1999</year></pub-date><volume>80</volume><issue>3-4</issue><fpage>396</fpage><lpage>402</lpage><history><date date-type="received"><day>26</day><month>03</month><year>1998</year></date><date date-type="rev-recd"><day>24</day><month>06</month><year>1998</year></date><date date-type="accepted"><day>27</day><month>06</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Anaemia commonly occurs in cancer patients receiving chemotherapy, often necessitating blood transfusion. This multicentre study was designed to evaluate the efficacy and safety of epoetin &#x003b1; in preventing the decline in haemoglobin (Hb) level, and to determine whether the transfusion requirement could be reduced, in patients receiving 4&#x02013;6 cycles of primarily platinum-based combination cyclic chemotherapy for small cell lung cancer (SCLC). A total of 130 non-anaemic SCLC patients were randomized to receive no additional treatment (<italic>n</italic> = 44), epoetin &#x003b1; 150 IU kg<sup>&#x02212;1</sup> subcutaneously (s.c.) three times a week (<italic>n</italic> = 42) or 300 IU kg<sup>&#x02212;1</sup> s.c. three times a week (<italic>n</italic> = 44). Reductions in epoetin &#x003b1; dosage were made during the study if Hb level increased to &#x0003e;15 g dl<sup>&#x02212;1</sup>. The mean weekly dosage was 335 and 612 IU kg<sup>&#x02212;1</sup>, respectively, in the two active treatment groups. Significantly fewer (<italic>P</italic> &#x0003c; 0.05) epoetin &#x003b1;-treated patients experienced anaemia (Hb &#x0003c; 10 g dl<sup>&#x02212;1</sup>) during the course of chemotherapy (300 IU kg<sup>&#x02212;1</sup>, 39&#x00025;; 150 IU kg<sup>&#x02212;1</sup>, 48&#x00025;; untreated, 66&#x00025;). This was reflected in the significantly lower number of treated patients transfused [300 IU kg<sup>&#x02212;1</sup>, 20&#x00025; (<italic>P</italic> &#x0003c; 0.001); 150 IU kg<sup>&#x02212;1</sup>, 45&#x00025; (<italic>P</italic> &#x0003c; 0.05); untreated, 59&#x00025;]. Epoetin &#x003b1; was well-tolerated, and there was no evidence of sustained, clinically significant, hypertension. In summary, epoetin &#x003b1; is effective and well-tolerated in maintaining Hb level and reducing transfusion requirement in patients undergoing cyclic chemotherapy for SCLC. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>epoetin prevents chemotherapy SCLC anaemia</kwd></kwd-group></article-meta></front></article>
